Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...

Drug toxicity: Drug–Drug Interaction

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...

Drug toxicity: Idiosyncratic Reactions

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Analysis of the expression of the Serpina1 gene in SARS-CoV-2 infection: study of a new biomarker.

Revista clinica espanola·2024

Same author

Safe alternatives in heart failure. Time to change paradigms.

Revista clinica espanola·2022

Same author

[Acute sialadenitis by iodine contrast medium administration].

Anales del sistema sanitario de Navarra·2021

Same author

Prognostic value of multimodal assessment of congestion in acute heart failure.

Revista clinica espanola·2021

Same author

Prognostic value of multimodal assessment of congestion in acute heart failure.

Revista clinica espanola·2020

Same author

Stress-induced hyperglycemia on complications in non-critically elderly hospitalized patients.

Revista clinica espanola·2018

Same journal

The place of the TAPSE/PASP in the diagnosis of right heart dysfunction in critically ill patients.

Medicina intensiva·2026

Same journal

Advanced circulatory support in oncologic patients with refractory cardiorespiratory failure.

Medicina intensiva·2026

Same journal

Breath stacking and the challenge of inferring mechanism from ventilator waveforms.

Medicina intensiva·2026

Same journal

Beyond authority: ICU leadership, accountability, and the responsibility to step down.

Medicina intensiva·2026

Same journal

Bleeding during VV-ECMO: clinicopathological correlation.

Medicina intensiva·2026

Same journal

Prolonged mechanical ventilation and tracheostomised Paediatric.

Medicina intensiva·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 17, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

[Metformin-associated hepatotoxicity].

S Olivera-González¹, B de Escalante-Yangüela, C Velilla-Soriano

¹Servicio de Medicina Interna, Hospital Clínico Universitario Lozano Blesa, Zaragoza, España. susana.olivera@yahoo.es

Medicina Intensiva

|January 5, 2010

Summary

This summary is machine-generated.

Metformin, a common type 2 diabetes drug, can rarely cause severe liver injury. This case highlights the importance of monitoring liver function in patients using metformin.

More Related Videos

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

Related Experiment Videos

Last Updated: Jun 17, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

Area of Science:

Pharmacology
Hepatology
Endocrinology

Background:

Metformin is a first-line oral antihyperglycemic agent for type 2 diabetes.
Gastrointestinal side effects are common, but severe hepatotoxicity is rare.
Contraindications include renal, liver, or heart insufficiency due to lactic acidosis risk.

Observation:

A patient with type 2 diabetes recently initiated on metformin presented with serious liver injury.
The patient's clinical presentation suggested drug-induced liver injury.
No other confounding factors for liver dysfunction were immediately apparent.

Findings:

The patient developed significant liver enzyme elevations after starting metformin.
Hepatotoxicity was suspected as the cause of the liver injury.
The patient experienced a favorable clinical outcome and liver function recovery after metformin discontinuation.

Implications:

This case underscores the potential for metformin-induced hepatotoxicity, although rare.
Vigilance in monitoring liver function is warranted in patients on metformin therapy.
Further research may be needed to elucidate the mechanisms of metformin hepatotoxicity.